SB 202190
Catalog Number : 1523072
description
SB 202190 is a selective and potent p38 MAP kinases inhibitor, binding to its ATP pocket. It has negligible inhibiting properties on other MAP kinases such as ERKs and JNKs. SB 202190 is reported to be used to induce cardiomyocyte differentiation from human embryonic stem cells and increase neural stem cell self-renewal.
Additional Information
|
Applications:
|
FA
|
|
Synonyms:
|
SB-202190, SB202190, FHPI, 4-[4-(4-Fluorphenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol
|
|
Formulation:
|
Crystalline solid
|
|
Chemical Name:
|
4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one
|
|
Molecular Formula:
|
C20H14FN3O |
|
Molecular Weight: |
331.3
|
|
CAS Number
|
152121-30-7
|
|
Purity:
|
≥98%
|
|
Storage Conditions:
|
Product should be kept at -20°C.
|
|
References:
|
Nemoto, S., Xiang, J., Huang, S., & Lin, A. (1998). Induction of apoptosis by SB202190 through inhibition of p38β mitogen-activated protein kinase. Journal of Biological Chemistry, 273(26), 16415-16420. Manthey, C. L., Wang, S. W., Kinney, S. D., & Yao, Z. (1998). SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. Journal of leukocyte biology,64(3), 409-417. Hirosawa, M., Nakahara, M., Otosaka, R., Imoto, A., Okazaki, T., & Takahashi, S. (2009). The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leukemia research,33(5), 693-699. |